Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - peginterferon alfa-2a 360 µg/ml - solution for injection - 180 mcg/0.5ml - active: peginterferon alfa-2a 360 µg/ml excipient: acetic acid benzyl alcohol glacial acetic acid sodium acetate soln 10% polysorbate 80 sodium acetate trihydrate sodium chloride water for injection - latest regulatory activity

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 180 µg/ml - solution for injection - 180 mcg/ml - active: peginterferon alfa-2a 180 µg/ml excipient: acetic acid benzyl alcohol glacial acetic acid sodium acetate soln 10% polysorbate 80 sodium acetate trihydrate sodium chloride water for injection

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 270 µg/ml; ribavirin 200mg;  ;   - combination - 135µg/0.5ml + 200mg - active: peginterferon alfa-2a 270 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 360 µg/ml; ribavirin 200mg;  ;   - combination - 180µg/0.5ml + 200mg - active: peginterferon alfa-2a 360 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 6 miu/ml;   - solution for injection - 3miu/0.5ml - active: interferon alfa-2a 6 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 12 miu/ml;   - solution for injection - 6miu/0.5ml - active: interferon alfa-2a 12 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 18 miu/ml;   - solution for injection - 9miu/0.5ml - active: interferon alfa-2a 18 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

Европейский союз - английский - EMA (European Medicines Agency)

pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4.4 and 5.1). paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. with respect to the decision to initiate treatment in paediatric patients see sections 4.2, 4.4 and 5.1. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4.2, 4.4 and 5.1). for hepatitis c virus (hcv) genotype specific activity, see sections 4.2 and 5.1. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. when deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. the reversibility of growth inhibition is uncertain. the decision to treat should be made on a case by case basis (see section 4.4).,

Европейский союз - английский - EMA (European Medicines Agency)

schering-plough europe - interferon alfa-2b - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b: treatment of adult patients with chronic hepatitis b associated with evidence of hepatitis b viral replication (presence of hbv-dna and hbeag), elevated alanine aminotransferase (alt) and histologically proven active liver inflammation and/or fibrosis.chronic hepatitis c:adult patients:introna is indicated for the treatment of adult patients with chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv (see section 4.4).the best way to use introna in this indication is in combination with ribavirin.chidren and adolescents:introna is intended for use, in a combination regimen with ribavirin, for the treatment of children and adolescents 3 years of age and older, who have chronic hepatitis c, not previously treated, without liver decompensation, and who are positive for serum hcv-rna. the decision to treat should be made on a case by case basis, taking into account any evidence of disease progression such as hepatic inflammation and fibrosis, as well as prognostic factors for response, hcv genotype and viral load. the expected benefit of treatment should be weighed against the safety findings observed for paediatric subjects in the clinical trials (see sections 4.4, 4.8 and 5.1).

Канада - английский - Health Canada

merck canada inc - interferon alfa-2b; water - kit - 18miu; 1ml - interferon alfa-2b 18miu; water 1ml - interferons